🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Paul Tudor Jones’s REGN Holdings & Trades

First Buy
Q2 2013
Duration Held
41 Quarters
Largest Add
Q1 2025
+97,523 Shares
Current Position
37,604 Shares
$28.51 M Value

Paul Tudor Jones's REGN Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 37,604 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $28.51 M, representing 0.04% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 41 quarters.

Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 97,523 shares. Largest reduction occurred in Q3 2025, reducing 84,550 shares.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's Regeneron Pharmaceuticals (REGN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Regeneron Pharmaceuticals (REGN) Trades by Paul Tudor Jones

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +37,604 New Buy 37,604 $758.27
Q3 2025 -84,550 Sold Out 0 $0.00
Q2 2025 -41,543 Reduce 32.95% 84,550 $525.00
Q1 2025 +97,523 Add 341.35% 126,093 $634.23
Q4 2024 -9,081 Reduce 24.12% 28,570 $712.33
Q3 2024 +37,651 New Buy 37,651 $1051.24
Q4 2023 -5,799 Sold Out 0 $0.00
Q3 2023 -7,847 Reduce 57.50% 5,799 $822.96
Q2 2023 +10,574 Add 344.21% 13,646 $718.54
Q1 2023 -542 Reduce 15.00% 3,072 $0.82
Q4 2022 +3,614 New Buy 3,614 $0.72
Q3 2022 -1,690 Sold Out 0 $0.00
Q2 2022 +1,690 New Buy 1,690 $591.12
Q3 2021 -1,591 Sold Out 0 $0.00
Q2 2021 +1,591 New Buy 1,591 $558.77
Q2 2020 -2,426 Sold Out 0 $0.00
Q1 2020 -2,670 Reduce 52.39% 2,426 $488.46
Q4 2019 +5,096 New Buy 5,096 $375.39
Q3 2019 -785 Sold Out 0 $0.00
Q2 2019 -1,650 Reduce 67.76% 785 $313.38
Q1 2019 +2,435 New Buy 2,435 $410.68
Q4 2018 -1,278 Sold Out 0 $0.00
Q3 2018 -7,754 Reduce 85.85% 1,278 $403.76
Q2 2018 +9,032 New Buy 9,032 $345.00
Q1 2018 -4,017 Sold Out 0 $0.00
Q4 2017 +4,017 New Buy 4,017 $375.90
Q2 2017 -600 Sold Out 0 $0.00
Q1 2017 +600 New Buy 600 $388.33
Q4 2016 -4,608 Sold Out 0 $0.00
Q3 2016 +1,652 Add 55.89% 4,608 $402.13
Q2 2016 +2,956 New Buy 2,956 $349.12
Q1 2016 -700 Sold Out 0 $0.00
Q4 2015 -390 Reduce 35.78% 700 $542.86
Q3 2015 +690 Add 172.50% 1,090 $465.14
Q2 2015 +400 New Buy 400 $510.00
Q4 2014 -2,499 Sold Out 0 $0.00
Q3 2014 +2,499 New Buy 2,499 $360.54
Q2 2014 -893 Sold Out 0 $0.00
Q1 2014 +893 New Buy 893 $300.11
Q3 2013 -1,600 Sold Out 0 $0.00
Q2 2013 +1,600 Add 0.00% 1,600 $225.00

Paul Tudor Jones's Regeneron Pharmaceuticals Investment FAQs

Paul Tudor Jones first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2013, acquiring 1,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held Regeneron Pharmaceuticals, Inc. (REGN) for 41 quarters since Q2 2013.

Paul Tudor Jones's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2025, adding 126,093 shares worth $79.97 M.

According to the latest 13F filing for Q3 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 37,604 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $28.51 M.

As of the Q3 2026 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.04% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.

Paul Tudor Jones's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 126,093 shares, as reported at the end of Q1 2025.